Table 1.
Surveillance, Epidemiology, and End Results (SEER) cancer incidence rate trends with joinpoint analyses (up to three joinpoints allowed) for 1992–2007 for the top 15 cancers, by sex, for all races*
| Sex/cancer site or type | Joinpoint analyses (1992–2007)† |
|||||||||
| Trend 1 |
Trend 2 |
Trend 3 |
Trend 4 |
AAPC‡ |
||||||
| Years | APC§ | Years | APC§ | Years | APC§ | Years | APC§ | 1998–2007 | 2003–2007 | |
| All sites‖ | ||||||||||
| Both sexes | 1992–1994 | −3.2¶ | 1994–1999 | 0.4 | 1999–2007 | −1.0¶ | −0.8# | −1.0# | ||
| Delay adjusted | 1992–1994 | −3.1¶ | 1994–1999 | 0.4 | 1999–2007 | −0.8¶ | −0.7# | −0.8# | ||
| Men | 1992–1995 | −4.5¶ | 1995–2000 | 0.2 | 2000–2007 | −1.4¶ | −1.1# | −1.4# | ||
| Delay adjusted | 1992–1995 | −4.4¶ | 1995–2001 | 0.1 | 2001–2005 | −1.9¶ | 2005–2007 | 0.3 | −0.7# | −0.8 |
| Women | 1992–1998 | 0.8¶ | 1998–2007 | −0.8¶ | −0.8# | −0.8# | ||||
| Delay adjusted | 1992–1998 | 0.8¶ | 1998–2007 | −0.6¶ | −0.6# | −0.6# | ||||
| Children (age 0–14 y) | 1992–2007 | 0.4 | 0.4 | 0.4 | ||||||
| Delay adjusted | 1992–2007 | 0.5 | 0.5# | 0.5# | ||||||
| Children (age 0–19 y) | 1992–2007 | 0.5¶ | 0.5# | 0.5# | ||||||
| Delay adjusted | 1992–2007 | 0.6¶ | 0.6# | 0.6# | ||||||
| Top 15 cancers for men** | ||||||||||
| Prostate | 1992–1995 | −11¶ | 1995–2001 | 1.8¶ | 2001–2005 | −4.3¶ | 2005–2007 | 2.2 | −0.9 | −1.1 |
| Delay adjusted | 1992–1995 | −11¶ | 1995–2001 | 1.8¶ | 2001–2005 | −4.2¶ | 2005–2007 | 3.0 | −0.6 | −0.6 |
| Lung and bronchus | 1992–2007 | −2.1¶ | −2.1# | −2.1# | ||||||
| Delay adjusted | 1992–2007 | −2¶ | −2.0# | −2.0# | ||||||
| Colon and rectum | 1992–1995 | −2.7¶ | 1995–1998 | 1.7 | 1998–2007 | −3.0¶ | −3.0# | −3.0# | ||
| Delay adjusted | 1992–1995 | −2.6¶ | 1995–1998 | 1.7 | 1998–2007 | −2.9¶ | −2.9# | −2.9# | ||
| Urinary bladder | 1992–2007 | −0.2 | −0.2 | −0.2 | ||||||
| Delay adjusted | 1992–2007 | −0.1 | −0.1 | −0.1 | ||||||
| Non-Hodgkin lymphoma | 1992–2007 | −0.1 | −0.1 | −0.1 | ||||||
| Delay adjusted | 1992–2007 | 0.0 | 0.0 | 0.0 | ||||||
| Melanoma of the skin | 1992–2007 | 2.2¶ | 2.2# | 2.2# | ||||||
| Delay adjusted | 1992–2007 | 2.4¶ | 2.4# | 2.4# | ||||||
| Kidney and renal pelvis | 1992–2007 | 1.9¶ | 1.9# | 1.9# | ||||||
| Delay adjusted | 1992–2007 | 2.0¶ | 2.0# | 2.0# | ||||||
| Oral cavity and pharynx | 1992–2007 | −1.5¶ | −1.5# | −1.5# | ||||||
| Delay adjusted | 1992–2007 | −1.4¶ | −1.4# | −1.4# | ||||||
| Leukemia | 1992–2007 | −0.6¶ | −0.6# | −0.6# | ||||||
| Delay adjusted | 1992–2007 | 0.1 | 0.1 | 0.1 | ||||||
| Pancreas | 1992–2007 | 0.2 | 0.2# | 0.2# | ||||||
| Delay adjusted | 1992–2003 | 0.0 | 2003–2007 | 1.9¶ | 0.8# | 1.9# | ||||
| Stomach | 1992–2007 | −1.9¶ | −1.9# | −1.9# | ||||||
| Delay adjusted | 1992–2007 | −1.9¶ | −1.9# | −1.9# | ||||||
| Liver and intrahepatic bile duct | 1992–2007 | 3.2¶ | 3.2# | 3.2# | ||||||
| Delay adjusted | 1992–2007 | 3.4¶ | 3.4# | 3.4# | ||||||
| Esophagus | 1992–2007 | −0.1 | −0.1 | −0.1 | ||||||
| Delay adjusted | 1992–2007 | 0.0 | 0.0 | 0.0 | ||||||
| Brain and other nervous system | 1992–2007 | −0.6¶ | −0.6# | −0.6# | ||||||
| Delay adjusted | 1992–2007 | −0.4¶ | −0.4# | −0.4# | ||||||
| Myeloma | 1992–2007 | −0.2 | −0.2 | −0.2 | ||||||
| Delay adjusted | 1992–2007 | 0.2 | 0.2 | 0.2 | ||||||
| Top 15 cancers for women** | ||||||||||
| Breast | 1992–1999 | 1.1¶ | 1999–2007 | −1.8¶ | −1.5# | −1.8# | ||||
| Delay adjusted | 1992–1999 | 1.1¶ | 1999–2007 | −1.8¶ | −1.4# | −1.8# | ||||
| Lung and bronchus | 1992–1998 | 0.6 | 1998–2007 | −0.6¶ | −0.6# | −0.6# | ||||
| Delay adjusted | 1992–1997 | 0.7 | 1997–2007 | −0.3¶ | −0.3# | −0.3# | ||||
| Colon and rectum | 1992–1995 | −1.9¶ | 1995–1998 | 2.0 | 1998–2007 | −2.3¶ | −2.3# | −2.3# | ||
| Delay adjusted | 1992–1995 | −1.8¶ | 1995–1998 | 2.0 | 1998–2007 | −2.2¶ | −2.2# | −2.2# | ||
| Corpus and uterus, NOS | 1992–2007 | −0.3¶ | −0.3# | −0.3# | ||||||
| Delay adjusted | 1992–2007 | −0.2¶ | −0.2# | −0.2# | ||||||
| Non-Hodgkin lymphoma | 1992–2004 | 1.2¶ | 2004–2007 | −1.8 | 0.2 | −1.1 | ||||
| Delay adjusted | 1992–2004 | 1.3¶ | 2004–2007 | −1.2 | 0.4 | −0.6 | ||||
| Thyroid | 1992–1998 | 3.8¶ | 1998–2007 | 6.4¶ | 6.4# | 6.4# | ||||
| Delay adjusted | 1992–1998 | 3.8¶ | 1998–2007 | 6.6¶ | 6.6# | 6.6# | ||||
| Melanoma of the skin | 1992–1997 | 3.9¶ | 1997–2007 | 1.5¶ | 1.5# | 1.5# | ||||
| Delay adjusted | 1992–2007 | 2.2¶ | 2.2# | 2.2# | ||||||
| Ovary‖ | 1992–2001 | −0.6¶ | 2001–2007 | −2.0¶ | −1.5# | −2.0# | ||||
| Delay adjusted‖ | 1992–1996 | −1.5 | 1996–2001 | 0.2 | 2001–2004 | −2.9 | 2004–2007 | −0.4 | −1.0 | −1.0 |
| Kidney and renal pelvis | 1992–2007 | 2.3¶ | 2.3# | 2.3# | ||||||
| Delay adjusted | 1992–1998 | 1.2 | 1998–2007 | 3.0¶ | 3.0# | 3.0# | ||||
| Pancreas | 1992–2007 | 0.4¶ | 0.4# | 0.4# | ||||||
| Delay adjusted | 1992–2000 | −0.1 | 2000–2007 | 1.3¶ | 1.0# | 1.3# | ||||
| Leukemia | 1992–2007 | −0.3 | −0.3 | −0.3 | ||||||
| Delay adjusted | 1992–2007 | 0.5¶ | 0.5# | 0.5# | ||||||
| Urinary bladder | 1992–2004 | −0.2 | 2004–2007 | −2.7¶ | −1.0# | −2.1# | ||||
| Delay adjusted | 1992–2004 | −0.2 | 2004–2007 | −2.2 | −0.9# | −1.7# | ||||
| Cervix uteri | 1992–2007 | −2.9¶ | −2.9# | −2.9# | ||||||
| Delay adjusted | 1992–2007 | −2.8¶ | −2.8# | −2.8# | ||||||
| Oral cavity and pharynx | 1992–2007 | −1.2¶ | −1.2# | −1.2# | ||||||
| Delay adjusted | 1992–2007 | −1.1¶ | −1.1# | −1.1# | ||||||
| Brain and other nervous system | 1992–2007 | −0.2 | −0.2 | −0.2 | ||||||
| Delay adjusted | 1992–2007 | 0.0 | 0.0 | 0.0 | ||||||
AAPC = average annual percent change; APC = annual percent change; NOS = not otherwise specified. Source: SEER-13 areas covering about 14% of the US population (Connecticut, Hawaii, Iowa, Utah, New Mexico, the Alaska Native Tumor Registry, rural Georgia, and the metropolitan areas of San Francisco, Los Angeles, San Jose-Monterey, Detroit, Atlanta, and Seattle-Puget Sound). Nonadjusted rates and rates that were adjusted for delays in reporting are shown.
Joinpoint analyses with up to three joinpoints yielding up to four trend segments (Trend 1–Trend 4) were based on rates per 100 000 persons and were age standardized to the 2000 US standard population (19 age groups: <1, 1–4, 5–9, 10–14, … , 80–84, >85 years, Census P25-1130). Joinpoint analysis used the Joinpoint Regression Program, Version 3.4.3. April 2010, Surveillance Research Program, National Cancer Institute.
AAPC is a weighted average of the APCs calculated by joinpoint.
APC is based on rates that were age standardized to the 2000 US standard population (19 age groups: <1, 1–4, 5–9, 10–14, … , 80–84, >85 years, Census P25–1130).
All sites exclude myelodysplastic syndromes and borderline tumors; ovary excludes borderline tumors.
APC is statistically significantly different from zero (two-sided t test, P < .05).
AAPC is statistically significantly different from zero (two-sided Z test, P < .05).
The top 15 cancers were selected based on the sex-specific age-standardized incidence rates for 2003–2007 for all races combined and listed in rank order.